摘要
目的研究直肠癌术中腹腔植入5-氟尿嘧啶(5-Fu)缓释剂的治疗效果及安全性。方法随机选取该院2014年1月—2016年12月收治的80例直肠癌患者作为研究对象,根据随机数字法,将80例直肠癌患者分成两组,其中40例患者为对照组仅实施根治术治疗,另外40例患者为观察组于术中在患者腹腔植入5-氟尿嘧啶缓释剂治疗,对比两组患者手术前后各项指标变化情况,术后切口感染率、肠道功能恢复时间、住院时间等。结果术后观察组CD3+(35.12±4.75)%,明显比对照组(48.31±8.69)%,低(P<0.05),其他免疫指标差异无统计学意义(P>0.05);观察组术后切口感染率(15.0%)明显高于对照组(2.5%),观察组肠道功能恢复时间(105.8±8.50)h长于对照组(91.2±5.90)h,两组对比差异有统计学意义(P<0.05);两组住院时间对比差异无统计学意义(P>0.05)。结论直肠癌患者术中腹腔植入5-氟尿嘧啶缓释剂治疗安全可靠,但是,会增加患者切口感染率,延长肠道功能恢复时间,抑制患者的免疫功能,临床值得推广应用。
Objective To research the treatment effect and safety of implanting sustained release 5-fluorouracil in abdominal in the rectal carcinoma surgery. Methods 80 cases of patients with rectal carcinoma admitted and treated in our hospital from January 2014 to December 2016 were randomly selected and randomly divided into two groups with 40 cases in each,the control group were only treated with radical operation, while the observation group were treated with implanting sustained release 5-fluorouracil in abdominal, and changes of various indexes including postoperative incision infection rate,recovery time of intestinal function and length of stay before and after operation were compared between the two groups.Results The CD3+ in the observation group was obviously lower than that in the control group after operation [(35.12 ±4.75)% vs(48.31±8.69)%](P<0.05), and there were no obvious differences in the other immune indexes(P>0.05), and the incision infection rate after operation was obviously higher than that in the control group(15.0% vs 2.5%), and the recovery time of intestinal function in the observation group was longer than that in the control group[(105.8±8.50)h vs(91.2±5.90)h],and the differences were obvious(P<0.05), and there was no obvious difference in the length of stay between the two groups(P >0.05). Conclusion The treatment of implanting sustained release 5-fluorouracil in abdominal in the rectal carcinoma surgery is safe and reliable, however, it can increase the incision infection rate of patients, prolong the recovery time of intestinal function and suppress the immune function of patients, and it is worth promotion and application.
作者
王展梅
高镨月
WANG Zhan-mei GAO Pu-yue(Department of Chemotherapy, Qilu Hospital of Shandong University, Qingdao, Shandong Province, 266000 China Digestive System Department, Qilu Hospital of Shandong University, Qingdao, Shandong Province, 266000 China)
出处
《中外医疗》
2017年第11期132-134,共3页
China & Foreign Medical Treatment
关键词
直肠癌
腹腔
5-氟尿嘧啶
缓释剂
安全性
Rectal carcinoma
Abdominal
5-fluorouracil
Sustained release
Safety